CCO has reversed course this week, falling 6.5% to CAD 144.56 — the stock that was bucking the uranium sector's drift just days ago is now moving squarely with it.
The June 24 note flagged Cameco outperforming peers as the broader complex stalled. That divergence has closed sharply. NXE dropped 9.6% on the week, DML fell 6.5%, UEC shed 6.0%, and ISO lost 6.8%. Cameco's 6.5% decline puts it firmly back in the middle of the pack. The brief leadership premium has been fully given back, and the stock is now down about 6.7% on the month — erasing the gains that had looked durable as recently as last Tuesday.
The positioning picture remains genuinely relaxed, despite the price weakness. Short interest has barely moved on the week, edging down fractionally to 0.71% of free float — essentially unchanged from the 0.72% reading noted on June 24. The 30-day build of around 30% in short shares is real, but the absolute level is still too low to read as conviction from the bear side. What's more, the lending market is looser than it has been all year: availability has jumped to 6,765% — meaning shares available to borrow outnumber shares currently borrowed by nearly 68 to one — up sharply from around 5,000% last week and well above any reading in the past 52 weeks. Cost to borrow has drifted lower to 0.47%, its cheapest level in over a month. The message from the borrow market is unambiguous: there is no squeeze dynamic, no supply constraint, and no sign that short-side pressure is driving the week's decline.
The factor picture offers a mild counterweight to the price action. The ORTEX short score sits at 27.4 — low on the scale and essentially flat across the past two weeks — consistent with a stock where short-side momentum is absent. The dividend score ranks in the 99th percentile, though the most recent dividend data in the system is from 2022 and should be treated as illustrative rather than current. EPS momentum scores are solid at the 71st percentile on the 30-day measure, and EPS surprise ranks near the median. On valuation, the trailing P/E runs near 73x and EV/EBITDA around 31x — neither cheap, but both have compressed modestly over the past 30 days as the stock has pulled back. Analyst data in the system is stale by several years and has been excluded.
Institutional positioning shows a mixed picture at the margin. BlackRock added around 77,000 shares in Q1, JP Morgan Asset Management added 180,000, and Goldman Sachs and Amova both built positions. T. Rowe Price trimmed by roughly 327,000 shares and UBS cut by around 109,000. The net flow is positive but not dramatic — a continuation of the gradual institutional accumulation that has characterized the stock over recent quarters rather than a decisive reallocation. Insider activity is similarly low-signal: two small VP-level sells in late June totalling under CAD 70,000 combined, both flagged at low significance.
Q2 earnings are scheduled for July 31. With the stock giving back its June outperformance and the peer group broadly weaker, the next focal point is whether the uranium spot price and utility contracting commentary in that release can offer a reason to re-establish the premium that briefly appeared earlier this month.
See the live data behind this article on ORTEX.
Open CCO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
